HepatoDetect – Encouraging first results

HepatoDetect Shows Strong Potential for Early HCC Detection

HepatoDetect, our AI-driven liquid biopsy platform designed for the early detection of hepatocellular carcinoma (HCC) in patients with cirrhosis, has delivered promising preliminary results. In an initial analysis of cell-free DNA (cfDNA) methylation patterns, the platform effectively distinguished patients with both cirrhosis and HCC from those with cirrhosis alone, demonstrating robust performance across all stages of disease.

These early findings underscore HepatoDetect’s potential as a powerful tool for early screening, diagnosis, and ongoing monitoring of HCC in clinical settings.